This trial is testing whether adding immunotherapy or a PARP inhibitor to thoracic radiation therapy is safe and effective in people with ES-SCLC who have responded to first-line platinum-based chemotherapy.
2 Primary · 2 Secondary · Reporting Duration: Up to 12 months
25 Total Participants · 4 Treatment Groups
Primary Treatment: Thoracic Radiotherapy · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: